Finance
Samaritan Pharmaceuticals to devote much of $40 million dollar financing to R&D
Published in AIDS Weekly, March 13th, 2006
According to BioCentury, Strategy-The Inside Story, "There is really only one thing that sustainable companies must do: make sure the pipeline is full of products that will come on the market at reasonable intervals and provide reasonable levels of revenue. Given the reality of pharmaceutical failure rates, the characteristics of successful business builders are thus fairly straightforward: they spend enough on R&D and do enough partnering and acquisitions to keep the compounds flowing."
Dr....
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
Source: AIDS Weekly (2006-03-13)
More Articles from AIDS Weekly
- HIV/AIDS Drug Development
Lamivudine and siRNA-M184V inhibits replication of wild-type and variant M184V HIV - HIV/AIDS Drug Resistance
HIV genotypic mutation frequencies identified in HAART-treated children in Cote d'Ivoire - HIV/AIDS Prognosis
C-reactive protein is a marker for human HIV-1 disease progression - HIV/AIDS Research
Methamphetamine stimulates interferon inducible genes in the HIV infected brain - Topical Microbicides
PRO 2000 gel inhibits HIV and HSV infection following vaginal application - Antiretroviral Therapy
Ritonavir has potent anti-NF-kappa B and antitumor effects - More from this issue of AIDS Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
